Literature DB >> 15259031

Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen.

Javier Hernández1, Kim Schoeder, Sylvie E Blondelle, Fancisco Garcia Pons, Yu Chun Lone, April Simora, Pierre Langlade-Demoyen, Darcy B Wilson, Maurizio Zanetti.   

Abstract

Human telomerase reverse transcriptase (hTRT) is a potential target for therapeutic vaccination against cancer. Therefore, it is critically important to identify T cell epitopes useful to induce cytotoxic T cell responses. Here we used a positional scanning combinatorial peptide library to identify peptide analogues for a previously characterized low affinity hTRT peptide (p572). From an initial library containing over 300 billion different peptides and through successive rounds of selection, we retained 72 candidate peptide analogues for further assessment of antigenicity and in vivo immunogenicity in HLA A2.1-transgenic mice. While antigenically cross-reactive with p572, only a fraction of these peptides was immunogenic in mice. Immunogenicity appeared to correlate with the stability of binding to the MHC molecule and the presence of HLA A2.1 anchor residues in position 2 and 9. Two peptides differing by five residues from the reference p572 (p49 and p50) were more effective than p572 in inducing CTL cross-reacting with p572 in HLA A2.1-transgenic mice. Both peptides also expanded specific CTL in peripheral blood lymphocytes of normal human volunteers ex vivo. The present study shows that positional scanning combinatorial peptide libraries can be used to identify hTRT peptide analogues for inclusion in a cancer vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259031     DOI: 10.1002/eji.200425134

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Telomerase reverse transcriptase as target for anti-tumor T cell responses in humans.

Authors:  Maurizio Zanetti; Xavier Hernandez; Pierre Langlade-Demoyen
Journal:  Springer Semin Immunopathol       Date:  2005-02-15

2.  Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.

Authors:  Rachel H McMahan; Jennifer A McWilliams; Kimberly R Jordan; Steven W Dow; Darcy B Wilson; Jill E Slansky
Journal:  J Clin Invest       Date:  2006-08-24       Impact factor: 14.808

3.  Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.

Authors:  Allan NoeDominguez-Romero; Rubén Zamora-Alvarado; Rodolfo Servín-Blanco; Erendira G Pérez-Hernández; Laura E Castrillon-Rivera; Maria Elena Munguia; Gonzalo Acero; Tzipe Govezensky; Goar Gevorkian; Karen Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).

Authors:  Zhong-Li Liao; Xu-Dong Tang; Mu-Han Lü; Yu-Yun Wu; Ya-Ling Cao; Dian-Chun Fang; Shi-Ming Yang; Hong Guo
Journal:  Cancer Sci       Date:  2012-09-28       Impact factor: 6.716

Review 5.  Mobilizing the low-avidity T cell repertoire to kill tumors.

Authors:  Rachel H McMahan; Jill E Slansky
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

6.  A T-cell receptor associated with naturally occurring human tumor immunity.

Authors:  Bianca D Santomasso; Wendy K Roberts; Ashby Thomas; Travis Williams; Nathalie E Blachère; Mark E Dudley; Alan N Houghton; Jerome B Posner; Robert B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

7.  Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.

Authors:  Andrea M Henle; Courtney L Erskine; Linda M Benson; Raphael Clynes; Keith L Knutson
Journal:  J Immunol       Date:  2012-11-23       Impact factor: 5.422

8.  Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8+ T-Cell Responses.

Authors:  Xuedan He; Shiqi Zhou; Breandan Quinn; Wei-Chiao Huang; Dushyant Jahagirdar; Michael Vega; Joaquin Ortega; Mark D Long; Fumito Ito; Scott I Abrams; Jonathan F Lovell
Journal:  Adv Sci (Weinh)       Date:  2021-10-30       Impact factor: 17.521

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.